MelBrainSys: Model-based prediction and experimental validation of novel therapeutic interventions for melanoma brain metastases
Malignant melanomas – a type of skin cancer – frequently forms metastases in early stages of the disease. These metastases can be developed in the brain or other organs. Therapies for frequently occurring brain metastases are still much less effective than for metastases in other organs. Why this is the case and how this might be overcome in the future is currently investigated by junior scientists from the Carl Gustav Carus Faculty of Medicine and the University Hospital Carl Gustav Carus in Dresden and the Heidelberg University Hospital. Within the framework of the BMBF-funded e:Med junior research alliance MelBrainSys, we will develop a highly innovative systems medicine approach that integrates medical bioinformatics, dermatooncology, immunology, and neurooncologyto computationally predict and experimentally validate new promising targets for the development of brain-specific therapies. This junior research alliance is funded for five years with 3.5 million euros by the Federal Ministry for Education and Research (BMBF).
further information: https://www.gesundheitsforschung-bmbf.de/de/melbrainsys-modellbasierte-vorhersage-und-experimentelle-validierung-neuer-therapeutischer-10933.php
Involved scientists
Publications
Coordinator
Dana Westphal, Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, TU Dresden
Partner
- Rebekka Wehner, Institut für Immunologie, Medizinische Fakultät Carl Gustav Carus, TU Dresden
- Matthia Andrea Karreman, Neurologische Klinik, Universitätsklinikum Heidelberg
Funding
BMBF, Förderkennzeichen: 01ZX1913B
